A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. We develop, manufacture and sell the AquaBeam Robotic System and HYDROS Robotic System, which are advanced, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. Each of our robotic systems employs a single-use disposable handpiece to deliver our proprietary Aquablation therapy, which combines real-time, multi-dimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. We designed our robotic systems to enable consistent and reproducible BPH surgery outcomes.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 308M | 308M | 224M | 136M | 75M | 34M |
| Net Income | -96M | -96M | -91M | -106M | -87M | -60M |
| EPS | $-1.72 | $-1.72 | $-1.75 | $-2.24 | $-1.96 | $-3.63 |
| Free Cash Flow | -58M | -58M | -104M | -133M | -83M | -58M |
| ROIC | -52.0% | -21.9% | -20.1% | -36.5% | -30.8% | -67.0% |
| Gross Margin | 63.7% | 63.7% | 61.1% | 52.2% | 49.4% | 46.0% |
| Debt/Equity | 0.21 | 0.21 | 0.20 | 0.28 | 0.39 | 0.20 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -104M | -104M | -97M | -109M | -81M | -54M |
| Operating Margin | -33.7% | -33.7% | -43.0% | -80.2% | -107.6% | -157.1% |
| ROE | -26.1% | -24.9% | -22.7% | -44.3% | -37.6% | -142.2% |
| Shares Outstanding | 56M | 56M | 52M | 47M | 44M | 44M |
| Metric | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | N/A | 34M | 75M | 136M | 224M | 308M | 308M |
| Gross Margin | N/A | 46.0% | 49.4% | 52.2% | 61.1% | 63.7% | 63.7% |
| R&D | 16M | 19M | 29M | 48M | 62M | 71M | 71M |
| SG&A | 30M | 51M | 89M | 132M | 171M | 229M | 229M |
| EBIT | -48M | -54M | -81M | -109M | -97M | -104M | -104M |
| Op. Margin | N/A | -157.1% | -107.6% | -80.2% | -43.0% | -33.7% | -33.7% |
| Net Income | -53M | -60M | -87M | -106M | -91M | -96M | -96M |
| Net Margin | N/A | -173.6% | -116.2% | -77.8% | -40.7% | -31.0% | -31.0% |
| Non-Recurring | 0 | 0 | 62K | 995K | 1.9M | 565K | 565K |
| Returns on Capital | |||||||
| ROIC | -37.9% | -67.0% | -30.8% | -36.5% | -20.1% | -21.9% | -52.0% |
| ROE | N/A | -142.2% | -37.6% | -44.3% | -22.7% | -24.9% | -26.1% |
| ROA | -42.1% | -25.9% | -27.0% | -29.7% | -17.1% | -18.3% | -18.8% |
| Cash Flow | |||||||
| Op. Cash Flow | -48M | -57M | -80M | -108M | -99M | -49M | -49M |
| Free Cash Flow | -49M | -58M | -83M | -133M | -104M | -58M | -58M |
| Owner Earnings | -53M | -64M | -94M | -131M | -136M | -103M | -103M |
| CapEx | 233K | 592K | 2.7M | 25M | 4.4M | 9.4M | 9.4M |
| Maint. CapEx | 2.9M | 3.3M | 2.8M | 3.8M | 5.2M | 6.4M | 6.4M |
| Growth CapEx | 0 | 0 | 0 | 21M | 0 | 3.0M | 3.0M |
| D&A | 2.9M | 3.3M | 2.8M | 3.8M | 5.2M | 6.4M | 6.4M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 2.2M | 3.8M | 10M | 19M | 32M | 48M | 48M |
| Debt Repayment | 0 | 0 | 50M | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||
| Net Debt | -45M | -250M | -145M | -178M | -587M | -495M | -208M |
| Cash & Equiv. | 100M | 304M | 222M | 257M | 334M | 287M | 287M |
| Long-Term Debt | 44M | 50M | 51M | 51M | 51M | 52M | 52M |
| Debt/Equity | -0.30 | 0.20 | 0.39 | 0.28 | 0.20 | 0.21 | 0.21 |
| Interest Coverage | -9.1 | -9.3 | -15.6 | -27.3 | -23.1 | -29.0 | -29.0 |
| Equity | -183M | 267M | 197M | 281M | 402M | 366M | 366M |
| Total Assets | 126M | 337M | 309M | 405M | 534M | 508M | 508M |
| Total Liabilities | 65M | 70M | 112M | 124M | 132M | 142M | 142M |
| Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -202M | -262M | -349M | -455M | -546M | -642M | -642M |
| Working Capital | 96M | 310M | 237M | 305M | 429M | 385M | 385M |
| Current Assets | 110M | 326M | 273M | 351M | 482M | 450M | 450M |
| Current Liabilities | 15M | 16M | 35M | 46M | 53M | 66M | 66M |
| Per Share Data | |||||||
| EPS | -14.47 | -3.63 | -1.96 | -2.24 | -1.75 | -1.72 | -1.72 |
| Owner EPS | -14.57 | -1.48 | -2.10 | -2.77 | -2.61 | -1.85 | -1.85 |
| Book Value | -49.92 | 6.12 | 4.43 | 5.94 | 7.70 | 6.58 | 6.58 |
| Cash Flow/Share | -13.19 | -1.31 | -1.81 | -2.28 | -1.90 | -0.88 | -1.60 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 3.7M | 43.7M | 44.5M | 47.3M | 52.2M | 55.6M | 55.6M |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | -14.3 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 4.1 | 9.1 | 7.2 | 10.7 | 4.9 | 3.7 |
| Price/Sales | N/A | 47.8 | 21.1 | 11.9 | 15.3 | 9.2 | 4.4 |
| FCF Yield | N/A | -5.2% | -4.6% | -6.6% | -2.4% | -3.2% | -4.3% |
| Market Cap | N/A | 1.1B | 1.8B | 2.0B | 4.3B | 1.8B | 1.4B |
| Avg. Price | N/A | 37.72 | 35.66 | 34.17 | 65.92 | 51.06 | 24.59 |
| Year-End Price | N/A | 25.27 | 40.30 | 42.95 | 82.01 | 32.41 | 24.59 |
PROCEPT BioRobotics Corp passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 54.5%.
PROCEPT BioRobotics Corp (PRCT) has a 5-year average return on invested capital (ROIC) of -35.3%. This is below average and may indicate limited pricing power.
PROCEPT BioRobotics Corp (PRCT) has a market capitalization of $1.4B. It is classified as a small-cap stock.
PROCEPT BioRobotics Corp (PRCT) does not currently pay a regular dividend.
PROCEPT BioRobotics Corp (PRCT) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
PROCEPT BioRobotics Corp (PRCT) reported annual revenue of $308 million in its most recent fiscal year, based on SEC EDGAR filings.
PROCEPT BioRobotics Corp (PRCT) has a net profit margin of -31.0%. The company is currently unprofitable.
PROCEPT BioRobotics Corp (PRCT) generated $-58 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
PROCEPT BioRobotics Corp (PRCT) has a debt-to-equity ratio of 0.21. This indicates a conservatively financed balance sheet.
PROCEPT BioRobotics Corp (PRCT) reported earnings per share (EPS) of $-1.72 in its most recent fiscal year.
PROCEPT BioRobotics Corp (PRCT) has a return on equity (ROE) of -24.9%. A negative ROE may indicate losses or negative equity.
PROCEPT BioRobotics Corp (PRCT) has a 5-year average gross margin of 54.5%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 6 years of financial data for PROCEPT BioRobotics Corp (PRCT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
PROCEPT BioRobotics Corp (PRCT) has a book value per share of $6.58, based on its most recent annual SEC filing.
No recent press releases.